Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05314517 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
A Phase 2 study, sponsored by Kinevant Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
NCT05314517: Clinical Trial Phase 2 study, sponsored by Kinevant Sciences.
NCT05314517 is a Phase 2 study that was terminated before completion, run by Kinevant Sciences. The registered enrollment target is 107 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05314517, a Phase 2 study, was terminated before completion, sponsored by Kinevant Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).
Primary Outcome
Rescue events included: Participants with worsening sarcoidosis requiring rescue treatment; and participants failing to follow protocol defined concomitant sarcoidosis medication requirements (oral corticosteroids \[OCS\] taper/immunosuppressive therapy \[IST\] removal/prohibited medication). Participants with premature treatment discontinuation in the DB period without rescue event were considered as with missing rescue event status and excluded from analysis.
Interventions
- DRUG Placebo
- DRUG Namilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2025-04-09 |
| Phase | Phase 2 |
Why NCT05314517 stopped before completion
NCT05314517 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05314517 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05314517 about?
NCT05314517 is a clinical study titled "A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis". This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).
What is the current status of trial NCT05314517?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2022-08-31. Estimated completion is 2025-04-09.
What interventions are being tested in trial NCT05314517?
The interventions under investigation include: Placebo (DRUG), Namilumab (DRUG).
Who is sponsoring clinical trial NCT05314517?
This trial is sponsored by Kinevant Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05314517's enrollment target sits among peer trials
107 646th of 2000 higher than 1,353 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI